Salud financiera de hoja de balance de Novonesis

Salud financiera controles de criterios 5/6

Novozymes tiene un patrimonio de accionistas total de DKK14.4B y una deuda total de DKK7.4B, lo que sitúa su ratio deuda-patrimonio en 51.6%. Sus activos y pasivos totales son DKK28.4B y DKK14.0B respectivamente. El BAIT de Novozymes es de DKK4.5B, por lo que su ratio de cobertura de intereses es de 53.8. Tiene efectivo e inversiones a corto plazo que ascienden a DKK1.1B.

Información clave

18.1%

Ratio deuda-patrimonio

€1.99b

Deuda

Ratio de cobertura de intereses	15.7x
Efectivo	€260.80m
Patrimonio	€11.01b
Total pasivo	€4.25b
Activos totales	€15.25b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK9.5B) de NVZM.F superan a sus pasivos a corto plazo (DKK7.3B).

Pasivo a largo plazo: Los activos a corto plazo (€1.8B) de NVZM.F no cubren sus pasivos a largo plazo (€2.6B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (15.7%) de NVZM.F se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de NVZM.F ha pasado de 36.2% a 18.1% en los últimos 5 años.

Cobertura de la deuda: La deuda de NVZM.F está bien cubierta por el flujo de caja operativo (56%).

Cobertura de intereses: Los pagos de intereses de la deuda de NVZM.F están bien cubiertos por el BAIT (53.8x cobertura).

Salud financiera de hoja de balance de Novonesis

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Novozymes A/S Announces Executive Appointments, Effective April 2021

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Novozymes A/S Announces Executive Changes

Novozymes A/S Announces Executive Changes

Firmenich and Novozymes Partner for Great-Tasting Yogurt with Unprecedented Sugar Reduction Performance

Novozymes A/S (CPSE:NZYM B) acquired Precisionbiotics Group Limited for €80 million.

Novozymes Omits to Provide Outlook for Second Half and Full Year of 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera